---
title: 'Activated Phosphoinositide 3-Kinase δ Syndrome: Update from the ESID Registry
  and comparison with other autoimmune-lymphoproliferative inborn errors of immunity'
authors:
- Maria Elena Maccari
- Martin Wolkewitz
- Charlotte Schwab
- Tiziana Lorenzini
- Jennifer W. Leiding
- Nathalie Aladjdi
- Hassan Abolhassani
- Wadih Abou-Chahla
- Alessandro Aiuti
- Saba Azarnoush
- Safa Baris
- Vincent Barlogis
- Federica Barzaghi
- Ulrich Baumann
- Marketa Bloomfield
- Nadezda Bohynikova
- Damien Bodet
- David Boutboul
- Giorgia Bucciol
- Matthew S. Buckland
- Siobhan O. Burns
- Caterina Cancrini
- Pascal Cathébras
- Marina Cavazzana
- Morgane Cheminant
- Matteo Chinello
- Peter Ciznar
- Tanya I. Coulter
- Maud D’Aveni
- Olov Ekwall
- Zelimir Eric
- Efrem Eren
- Anders Fasth
- Pierre Frange
- Benjamin Fournier
- Marina Garcia-Prat
- Martine Gardembas
- Christoph Geier
- Sujal Ghosh
- Vera Goda
- Lennart Hammarstrom
- Fabian Hauck
- Maximilian Heeg
- Edyta Heropolitanska-Pliszka
- Anna Hilfanova
- Stephen Jolles
- Elif Karakoc-Aydiner
- Gerhard R. Kindle
- Christian Klemann
- Patra Koletsi
- Sylwia Koltan
- Irina Kondratenko
- Julia Körholz
- Renate Krüger
- Eric Jeziorski
- Romain Levy
- Guillaume Le Guenno
- Guillaume Lefevre
- Vassilios Lougaris
- Antonio Marzollo
- Nizar Mahlaoui
- Marion Malphettes
- Andrea Meinhardt
- Etienne Merlin
- Isabelle Meyts
- Tomas Milota
- Fernando Moreira
- Despina Moshous
- Anna Mukhina
- Olaf Neth
- Jennifer Neubert
- Benedicte Neven
- Alexandra Nieters
- Raphaele Nove-Josserand
- Eric Oksenhendler
- Ahmet Ozen
- Peter Olbrich
- Antoinette Perlat
- Malgorzata Pac
- Jana Pachlopnik Schmid
- Lucia Pacillo
- Alba Parra-Martinez
- Olga Paschenko
- Isabelle Pellier
- Asena Pinar Sefer
- Alessandro Plebani
- Dominique Plantaz
- Seraina Prader
- Loic Raffray
- Henrike Ritterbusch
- Jacques G. Riviere
- Beatrice Rivalta
- Stephan Rusch
- Inga Sakovich
- Sinisa Savic
- Raphael Scheible
- Nicolas Schleinitz
- Catharina Schuetz
- Ansgar Schulz
- Anna Sediva
- Michaela Semeraro
- Svetlana O. Sharapova
- Anna Shcherbina
- Mary A. Slatter
- Georgios Sogkas
- Pere Soler-Palacin
- Carsten Speckmann
- Jean-Louis Stephan
- Felipe Suarez
- Alberto Tommasini
- Johannes Trück
- Annette Uhlmann
- Koen J. van Aerde
- Joris van Montfrans
- Horst von Bernuth
- Klaus Warnatz
- Tony Williams
- Austen JJ. Worth
- Winnie Ip
- Capucine Picard
- Emilie Catherinot
- Zohreh Nademi
- Bodo Grimbacher
- Lisa R. Forbes Satter
- Sven Kracker
- Anita Chandra
- Alison M. Condliffe
- Stephan Ehl
date: '2023-06-28'
publishDate: '2023-12-29T21:10:06.708485Z'
publication_types:
- 2
doi: 10.1016/j.jaci.2023.06.015
abstract: 'Background Activated phosphoinositide-3-kinase (PI3K) δ Syndrome (APDS)
  is an inborn error of immunity (IEI) with infection susceptibility and immune dysregulation,
  clinically overlapping with other conditions. Management depends on disease evolution,
  but predictors of severe disease are lacking. Objectives Report the extended spectrum
  of disease manifestations in APDS1 versus APDS2, compare these to CTLA-4 deficiency,
  NFκB1 deficiency, and STAT3 gain-of-function (GOF) disease; identify predictors
  of severity in APDS. Methods Data collection with the European Society for Immunodeficiencies
  (ESID)-APDS registry. Comparison with published cohorts of the other IEIs. Results
  The analysis of 170 APDS patients outlines high penetrance and early-onset of APDS
  compared to the other IEIs. The large clinical heterogeneity even in individuals
  with the same PIK3CD variant E1021K illustrates how poorly the genotype predicts
  the disease phenotype and course. The high clinical overlap between APDS and the
  other investigated IEIs suggests relevant pathophysiological convergence of the
  affected pathways. Preferentially affected organ systems indicate specific pathophysiology:
  bronchiectasis is typical of APDS1; interstitial lung disease and enteropathy are
  more common in STAT3 GOF and CTLA-4 deficiency. Endocrinopathies are most frequent
  in STAT3 GOF, but growth impairment is also common particularly in APDS2. Early
  clinical presentation is a risk factor for severe disease in APDS. Conclusion APDS
  illustrates how a single genetic variant can result in a diverse autoimmune-lymphoproliferative
  phenotype. Overlap with other IEI is substantial. Some specific features distinguish
  APDS1 from APDS2. Early-onset is a risk factor for severe disease course calling
  for specific treatment studies in younger patients.'
tags:
- APDS
- CTLA-4
- ESID
- IEI
- immunodeficiency
- NFκB1
- PI3K
- PIK3CD
- PIK3R1
- STAT3
links:
- name: URL
  url: https://www.sciencedirect.com/science/article/pii/S0091674923008126
---
